"Chlorambucil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
| Descriptor ID |
D002699
|
| MeSH Number(s) |
D02.455.526.728.650.156
|
| Concept/Terms |
Chlorambucil- Chlorambucil
- 4-(Bis(2-chloroethyl)amino)benzenebutanoic Acid
- N,N-Di-(2-chloroethyl)-p-aminophenylbutyric Acid
- Chloraminophene
- Chlorbutin
|
Below are MeSH descriptors whose meaning is more general than "Chlorambucil".
Below are MeSH descriptors whose meaning is more specific than "Chlorambucil".
This graph shows the total number of publications written about "Chlorambucil" by people in this website by year, and whether "Chlorambucil" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 1 | 2 |
| 2022 | 0 | 3 | 3 |
| 2023 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chlorambucil" by people in Profiles.
-
Oxidized Activated Charcoal Nanozymes: Synthesis, and Optimization for In Vitro and In Vivo Bioactivity for Traumatic Brain Injury. Adv Mater. 2024 Mar; 36(10):e2211239.
-
Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis. Leukemia. 2023 07; 37(7):1558-1560.
-
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022 06 14; 6(11):3440-3450.
-
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leuk Lymphoma. 2022 06; 63(6):1375-1386.
-
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na?ve chronic lymphocytic leukemia. Leukemia. 2022 04; 36(4):1171-1175.
-
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leuk Res. 2020 10; 97:106432.
-
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020 04 18; 395(10232):1278-1291.
-
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020 03; 34(3):787-798.
-
A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Haematologica. 2020 04; 105(4):e164-e168.
-
Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia. Haematologica. 2019 01; 104(1):9-12.